July 13, 2021
Sanofi said on July 12 that it has launched the Japan portion of its global PIII study for its adjuvanted recombinant protein vaccine for COVID-19 being developed jointly with GlaxoSmithKline. The randomized, double-blind placebo-controlled study will enroll more than 35,000...read more